Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints

Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial

Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board

Anavex Life Sciences Announces Participation at Worldwide NIH Panel at Rare Disease Day®

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine)

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 U.S Phase 2 Trial